Microneedling vs. Fractional Carbon Dioxide Laser Along With Topical Platelet-Rich Plasma for the Treatment of Acne Scars: A Randomized Controlled Study

Background: Atrophic scarring is a frequent and psychologically burdensome consequence of acne vulgaris. Microneedling (MN) and the fractional carbon dioxide laser (FCL) are used to resurface these scars, while platelet-rich plasma (PRP) serves as an adjunct rich in growth factors. Head-to-head evidence for two PRP-based combinations remains sparse, particularly in pigmented skin. This trial evaluated how MN paired with topical PRP compares with FCL paired with topical PRP, in both effectiveness and tolerability, for atrophic post-acne scarring. Objectives: To compare the efficacy, safety, and patient-reported outcomes of MN + topical PRP versus FCL + topical PRP in the treatment of post-acne scars. Materials and methods: This assessor-blinded randomized controlled trial was run at a tertiary-care teaching hospital in Bhubaneswar, Eastern India. Fifty-two individuals with atrophic post-acne scars were allocated in equal numbers to Group A (MN with topical PRP) or Group B (FCL with topical PRP), and 48 reached completion (25 in Group A, 23 in Group B). Each participant received three treatments spaced four weeks apart, assessed before the first session and one month after the last. The main endpoint was the change in the quantitative Goodman-Baron scar score. Additional endpoints were the qualitative grade, two patient-reported measures, the Visual Analogue Scale (VAS) and the Dermatology Life Quality Index (DLQI), and erythema, edema, and pain recorded 72 hours after treatment. All efficacy and safety comparisons were confined to per-protocol participants and used the Mann-Whitney U and Wilcoxon signed-rank tests. Results: Within each arm, quantitative scores fell significantly (p < 0.001). The median reduction from baseline reached 33.33% in Group A and 35.29% in Group B, a difference that was not statistically meaningful (U = 234.0, p = 0.273). Both the drop in VAS (U = 457.5, p < 0.001) and the gain in DLQI (U = 81.5, p < 0.001), however, favored FCL plus PRP, and a larger share of Group B attained macular-grade scarring (39.1% versus 16.0%). At 72 hours, laser-treated patients reported more erythema, edema, and pain (all p < 0.001), though these reactions were short-lived and eased with successive sessions. No serious adverse event occurred. Conclusion: Each combination delivered significant improvement in atrophic acne scarring, and their objective quantitative gains were similar. FCL plus PRP produced greater qualitative and patient-rated benefit but provoked more short-lived post-treatment inflammation, whereas MN plus PRP was better tolerated with reduced downtime. Ethics: Approved by the Institutional Ethics Committee (KIIT/KIMS/IEC/1563/2024) and CTRI registered (CTRI/2025/06/088199).

Authors

Publication Details

Journal
Cureus
Published
2026-11-21
DOI
https://doi.org/10.7759/cureus.120027
Primary Topic
Dermatologic Treatments and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Microneedling vs. Fractional Carbon Dioxide Laser Along With Topical Platelet-Rich Plasma for the Treatment of Acne Scars: A Randomized Controlled Study

Sibaram Panda, Mitanjali Sethy, Chinmoy Raj, Farheen Begum et al.
Cureus
Dermatologic Treatments and Research
article

Microneedling vs. Fractional Carbon Dioxide Laser Along With Topical Platelet-Rich Plasma for the Treatment of Acne Scars: A Randomized Controlled Study

Sibaram Panda, Mitanjali Sethy, Chinmoy Raj, Farheen Begum, Anisha Biswal, Debasmita Behera, Yash Dad, Laxman Besra
article en

Abstract

Background: Atrophic scarring is a frequent and psychologically burdensome consequence of acne vulgaris. Microneedling (MN) and the fractional carbon dioxide laser (FCL) are used to resurface these scars, while platelet-rich plasma (PRP) serves as an adjunct rich in growth factors. Head-to-head evidence for two PRP-based combinations remains sparse, particularly in pigmented skin. This trial evaluated how MN paired with topical PRP compares with FCL paired with topical PRP, in both effectiveness and tolerability, for atrophic post-acne scarring. Objectives: To compare the efficacy, safety, and patient-reported outcomes of MN + topical PRP versus FCL + topical PRP in the treatment of post-acne scars. Materials and methods: This assessor-blinded randomized controlled trial was run at a tertiary-care teaching hospital in Bhubaneswar, Eastern India. Fifty-two individuals with atrophic post-acne scars were allocated in equal numbers to Group A (MN with topical PRP) or Group B (FCL with topical PRP), and 48 reached completion (25 in Group A, 23 in Group B). Each participant received three treatments spaced four weeks apart, assessed before the first session and one month after the last. The main endpoint was the change in the quantitative Goodman-Baron scar score. Additional endpoints were the qualitative grade, two patient-reported measures, the Visual Analogue Scale (VAS) and the Dermatology Life Quality Index (DLQI), and erythema, edema, and pain recorded 72 hours after treatment. All efficacy and safety comparisons were confined to per-protocol participants and used the Mann-Whitney U and Wilcoxon signed-rank tests. Results: Within each arm, quantitative scores fell significantly (p < 0.001). The median reduction from baseline reached 33.33% in Group A and 35.29% in Group B, a difference that was not statistically meaningful (U = 234.0, p = 0.273). Both the drop in VAS (U = 457.5, p < 0.001) and the gain in DLQI (U = 81.5, p < 0.001), however, favored FCL plus PRP, and a larger share of Group B attained macular-grade scarring (39.1% versus 16.0%). At 72 hours, laser-treated patients reported more erythema, edema, and pain (all p < 0.001), though these reactions were short-lived and eased with successive sessions. No serious adverse event occurred. Conclusion: Each combination delivered significant improvement in atrophic acne scarring, and their objective quantitative gains were similar. FCL plus PRP produced greater qualitative and patient-rated benefit but provoked more short-lived post-treatment inflammation, whereas MN plus PRP was better tolerated with reduced downtime. Ethics: Approved by the Institutional Ethics Committee (KIIT/KIMS/IEC/1563/2024) and CTRI registered (CTRI/2025/06/088199).

Cureus
Dermatologic Treatments and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon